Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report

References

• Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217–237. doi:10.5306/wjco.v12.i4.217
   PubMed Web of Science ®Google Scholar
• Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040–1091. doi:10.1200/JCO.20.03570
   PubMed Web of Science ®Google Scholar
• Takahashi K, Seto Y, Okada K, et al. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. Thorac Cancer. 2020;11(3):581–587. doi:10.1111/1759-7714.13299
   PubMed Web of Science ®Google Scholar
• Oya Y, Kuroda H, Nakada T, Takahashi Y, Sakakura N, Hida T. Efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer with ALK rearrangement. Int J Mol Sci. 2020;21(7):2623. doi:10.3390/ijms21072623
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Von CE, Fuang HG. A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. Respir Med Case Rep. 2021;34:101478. doi:10.1016/j.rmcr.2021.101478
   PubMed Web of Science ®Google Scholar
• Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84. doi:10.1016/j.lungcan.2014.07.020
   PubMed Web of Science ®Google Scholar
• Yang Y, Huang J, Wang T, et al. Decoding the evolutionary response to ensartinib in patients with ALK-positive NSCLC by dynamic circulating tumor DNA sequencing. J Thorac Oncol. 2021;16(5):827–839. doi:10.1016/j.jtho.2021.01.1615
   PubMed Web of Science ®Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133. doi:10.1158/2159-8290.CD-16-0596
   PubMed Web of Science ®Google Scholar
• Yamagata A, Yokoyama T, Fukuda Y, Ishida T. Alectinib re-challenge in small cell lung cancer transformation after chemotherapy failure in a patient with ALK-positive lung cancer: a case report. Respir Med Case Rep. 2021;33:101440. doi:10.1016/j.rmcr.2021.101440
   PubMed Web of Science ®Google Scholar
• Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol. 2018;36(12):1199–1206. doi:10.1200/JCO.2017.76.2294
   PubMed Web of Science ®Google Scholar
• Speidel D. The role of DNA damage responses in p53 biology. Arch Toxicol. 2015;89(4):501–517. doi:10.1007/s00204-015-1459-z
   PubMed Web of Science ®Google Scholar
• Kron A, Alidousty C, Scheffler M, et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann Oncol. 2018;29(10):2068–2075. doi:10.1093/annonc/mdy333
   PubMed Web of Science ®Google Scholar
• Walter DM, Venancio OS, Buza EL, et al. Systematic in vivo inactivation of chromatin-regulating enzymes identifies Setd2 as a potent tumor suppressor in lung adenocarcinoma. Cancer Res. 2017;77(7):1719–1729. doi:10.1158/0008-5472.CAN-16-2159
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Matsumoto S, Takeuchi S, et al. Proteasome inhibition overcomes ALK-TKI resistance in ALK-rearranged/TP53-mutant NSCLC via noxa expression. Clin Cancer Res. 2021;27(5):1410–1420. doi:10.1158/1078-0432.CCR-20-2853
   PubMed Web of Science ®Google Scholar
• Assoun S, Theou-Anton N, Nguenang M, et al. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 2019;132:65–71. doi:10.1016/j.lungcan.2019.04.005
   PubMed Web of Science ®Google Scholar
• Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012–3024. doi:10.1158/1078-0432.CCR-16-2554
   PubMed Web of Science ®Google Scholar
• Lu M, Zhao B, Liu M, et al. Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy. NPJ Precis Oncol. 2021;5(1):51. doi:10.1038/s41698-021-00193-0
   PubMed Web of Science ®Google Scholar
• Leslie KK, Filiaci VL, Mallen AR, et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: an NRG Oncology study. Gynecol Oncol. 2021;161(1):113–121. doi:10.1016/j.ygyno.2021.01.025
   PubMed Web of Science ®Google Scholar
• Pao W, Ooi CH, Birzele F, et al. Tissue-specific immunoregulation: a call for better understanding of the “immunostat” in the context of cancer. Cancer Discov. 2018;8(4):395–402. doi:10.1158/2159-8290.CD-17-1320
   PubMed Web of Science ®Google Scholar
• Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475–1485. doi:10.1038/s12276-020-00500-y
   PubMed Web of Science ®Google Scholar
• Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539–549. doi:10.1158/0008-5472.CAN-12-2325
   PubMed Web of Science ®Google Scholar
• Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–115. doi:10.1111/imm.12036
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148. doi:10.1084/jem.20140559
   PubMed Web of Science ®Google Scholar